Is Wegovy Safe to Use? What the Evidence Says

What clinical trial data actually show about Wegovy's safety profile

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults without diabetes for 68 weeks. Participants taking semaglutide 2.4mg lost an average of around 15% of body weight, and the safety data collected alongside those results are what regulators used to grant UK authorisation. Gastrointestinal effects were the most common finding: nausea, diarrhoea, vomiting, constipation and reflux each appeared more often in the active group than in people taking a placebo. Crucially, the majority of these were rated mild to moderate, and they clustered around dose increases rather than persisting throughout treatment.

The NHS semaglutide medicines page lists these GI effects alongside other commonly reported symptoms, headache, fatigue, dizziness and injection-site reactions. None of that should be frightening. It does mean a prescriber needs to know your full medical history before treatment starts, which is exactly what the consultation process exists for. If you've been putting this off because the side-effect list looks long, you're not alone, it's one of the things our clinical team talks through most often.

The Black Triangle (▼) on Wegovy means Novo Nordisk and the MHRA are still collecting real-world safety data; it does not signal that the medicine is experimental. Many medicines carry this designation for several years after launch as a standard part of post-authorisation pharmacovigilance.

The side effects that need medical attention, and the ones that usually don't

Most people on Wegovy will experience some nausea, particularly when the dose steps up. Sipping fluids, eating smaller portions and avoiding high-fat meals helps considerably for a lot of patients. This is not a reason to stop treatment without speaking to a prescriber first.

There are, however, symptoms that warrant prompt medical help. The MHRA's Drug Safety Update of 29 January 2026 specifically highlighted acute pancreatitis as an infrequent but serious side effect: if you develop severe, persistent abdominal pain (especially pain that radiates through to the back, with or without vomiting) seek urgent care and tell the clinician you are taking a GLP-1 medicine. Gallbladder problems (sudden upper-right abdominal pain, fever, jaundice) are another reason to contact a doctor promptly. Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, severe rash) need emergency attention.

Dehydration is a real risk if vomiting or diarrhoea is severe. Kidney function can be affected when someone becomes significantly dehydrated, so keeping fluid intake up and contacting a GP if symptoms don't settle within a day or two matters. A full list of side effects and the complete contraindication profile is set out in the Patient Information Leaflet, always the definitive reference for your specific product.

If you experience anything that concerns you, our support team is available seven days a week, and the MHRA Yellow Card scheme allows any patient to report a suspected side effect directly to the regulator. Reporting helps build the UK's real-world safety evidence base.

Who Wegovy is not suitable for, and why that matters before you start

The MHRA licence sets out specific groups for whom Wegovy is not recommended. Pregnancy and breastfeeding are clear exclusions; anyone who becomes pregnant while on treatment should stop immediately and speak to their GP. The same applies if you are actively trying to conceive. Wegovy is not licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, should not take semaglutide. A history of pancreatitis, certain gastrointestinal conditions and some other comorbidities also require careful prescriber assessment before treatment is considered.

This is the part of the safety question that a legitimate prescriber takes seriously, and that a supplier offering semaglutide without a clinical assessment cannot address. Every consultation at nume is reviewed personally by a GPhC-registered Independent Prescriber who considers your full health picture, not just your BMI. For a broader look at how semaglutide's safety profile has been evaluated across the licensed population, the semaglutide safety overview goes deeper on the mechanism and risk context.

Long-term safety and ongoing monitoring

Wegovy has been in clinical use internationally since 2021 and in the UK since 2023. NICE's appraisal under TA875 recommends its use for a maximum of two years within a specialist weight management pathway, partly because longer-term data beyond the main trial windows are still accumulating, and partly because treatment is intended to complement sustained lifestyle change rather than replace it.

What the evidence does not show is any signal serious enough to have altered the UK licence or prompted a product withdrawal. Post-market surveillance continues through the Yellow Card scheme and Novo Nordisk's pharmacovigilance programme. If you want to understand what longer-term use looks like in practice, the page on Wegovy and long-term safety covers that specifically, including what happens when treatment is stopped. The full Wegovy side effects page also details frequency data by system if you want the granular breakdown, and if you're starting from first principles, our overview of whether Wegovy is safe sets out what the evidence base looks like at a clinical level, while the page on whether Wegovy is safe to take addresses the more personal question of what that means for an individual considering treatment. For those interested in how the injection itself is used safely (sites, rotation and storage) our Wegovy overview covers the practical detail alongside the clinical context.